非小细胞肺癌 (NSCLC) 是最常见的癌症类型之一，是全世界癌症相关死亡的主要原因。 NSCLC 的治疗取得了显着改善，特别是在过去 10 年中。通过低剂量 CT 对高危人群进行系统筛查、新型手术和放射治疗技术的实施以及对 NSCLC 更深入的生物学了解，带来了创新的全身治疗方案，改善了 NSCLC 患者的预后。在非转移性非小细胞肺癌中，局部晚期疾病中各种围手术期策略和辅助免疫治疗的结合似乎可以提高治愈率。在转移性非小细胞肺癌中，新药的使用可能会延长疾病控制时间并保持生活质量。预测性临床和遗传标记的进一步开发对于个体化治疗概念的下一步至关重要。© 2024。Springer Nature Limited。

Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose CT, the implementation of novel surgical and radiotherapeutic techniques and a deeper biological understanding of NSCLC that has led to innovative systemic treatment options have improved the prognosis of patients with NSCLC. In non-metastatic NSCLC, the combination of various perioperative strategies and adjuvant immunotherapy in locally advanced disease seem to enhance cure rates. In metastatic NSCLC, the implementation of novel drugs might prolong disease control together with preserving quality of life. The further development of predictive clinical and genetic markers will be essential for the next steps in individualized treatment concepts.© 2024. Springer Nature Limited.